LKFT · Lakefront Biotherapeutics NV
Market Cap
$1.76B
Shares
65.48M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.81
Open$27.30
Day$26.78–27.30
52W close$26.08–37.62
Avg vol 30d250K
Short int3.3M · 5.0% float · 14.0d
Short vol41%
Last earningsMay 7, 2026
DataJan 2020–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-17.6%
Trailing year
Short interest
5.0%
Latest settlement · 14.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−6%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
6%
near low
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−16%
trailing
YTD return
−18%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $28 › 200d $30 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.03% of float · ▲ +10.8% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
76 holders — near 3-yr low, contrarian setup
Squeeze score
58
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
29%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
2.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $28 › 200d $30 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +8 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.03% of float · ▲ +10.8% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
76 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $26
Now $27 · 6%
Range high $38
vs 200-day avg -12%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LKFT
this stock
Lakefront Biotherapeutics NV
|
$1.76B | -18.0% | — | — | 5.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LKFT | -7.6% | -4.4% | -16.2% | -5.9% | -18.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.5% | -2.6% | -34.1% | -5.6% | -30.1% |
Key facts
CIK
1421876
CUSIP
36315X101
13F (30d)
27 filings
27 filers
Visit website
Investor relations